Junqin He

发表

Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor‐associated endothelial cells

K. Do, I. Fidler, Toru Nakamura, 2006, The Prostate.

Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.

I. Fidler, R. Langley, D. Fan, 2005, Cancer research.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Jing Wang, Kwok-Kin Wong, J. Heymach, 2019, Cancer cell.

Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

Hu, Shuai, Alexa, 2020 .

Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice

I. Fidler, R. Langley, S. J. Kim, 2004, Cancer Research.

Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse.

I. Fidler, R. Langley, J. Papadopoulos, 2011, International immunopharmacology.

Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice

K. Aldape, W. Yung, I. Fidler, 2015, Clinical Cancer Research.

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jing Wang, C. Ren, M. Ha, 2021, Nature.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Jing Wang, Kwok-Kin Wong, V. Miller, 2020, Cancer cell.

Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations.

D. Gandara, F. Meric-Bernstam, J. Crawford, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Active specific immunotherapy against occult brain metastasis.

C. Bucana, I. Fidler, C. Donawho, 2003, Cancer research.

Active Specific Immunotherapy against Occult Brain Metastasis 1

C. Bucana, I. Fidler, C. Donawho, 2003 .

Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors

A. Sood, I. Fidler, P. Thaker, 2005, Clinical Cancer Research.

Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells.

I. Fidler, R. Langley, Qiuyu Wu, 2014, Neuro-oncology.

Altered regulation of HIF-1α in naïve- and drug-resistant EGFR mutant NSCLC: implications for a VEGF-dependent phenotype.

Jing Wang, J. Minna, I. Wistuba, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.

Do-Hyun Nam, Kenji Yokoi, Stanley R Hamilton, 2005, Cancer research.

Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.

I. Fidler, F. Lehembre, D. Fan, 2012, Translational oncology.

Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.

K. Do, I. Fidler, C. Logothetis, 2006, Journal of the National Cancer Institute.

Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model.

J. Papadopoulos, Yeup Yoon, Jang‐Seong Kim, 2012, Neoplasia.

Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain.

L. Cantley, I. Fidler, Yan Wang, 2015, Cancer research.

Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy.

G. Mills, Ju-Seog Lee, M. Hung, 2010, Neoplasia.

Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

Junqin He, Urs Regenass, I. Fidler, 2016, Neuro-oncology.

Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

I. Fidler, F. Lehembre, Emily C. Brantley, 2011, Neoplasia.

Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.

D. Nam, I. Fidler, J. Abbruzzese, 2005, Neoplasia.

Activation of the Platelet-Derived Growth Factor-Receptor Enhances Survival of Murine Bone Endothelial Cells 1

I. Fidler, R. Langley, D. Fan, 2004, Cancer Research.

Abstract 347: Identification of poziotinib alone or in combination with TDM1 as a pan-HER2 inhibitor

Limei Hu, M. Nilsson, Junqin He, 2019, Experimental and Molecular Therapeutics.

Abstract 601: Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer

I. Fidler, F. Lehembre, S. J. Kim, 2011 .

Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells.

I. Fidler, R. Langley, Qiuyu Wu, 2014, Neuro-oncology.

Abstract 3428: Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy

G. Mills, I. Fidler, R. Langley, 2010 .